Para citar este trabalho use um dos padrões abaixo:
Fusarium solani have been observed as emerging opportunistic pathogen, causing since skin infections (keratitis and onychomycosis) to systemic infections disseminated. Onychomycosis affects the nail plate with an incidence of up to 8% of the world population, whose prevalence among onicopathies may be 50%. Epidemiological studies have pointed an increase of onychomycosis caused by non-dermatophytic fungi, such as F. solani, among patients with some underlying disease, especially on the toenails. Among the antifungal options, the itraconazole (ITZ) has been the drug of choice for the onychomycosis treatment. Thus, to know the Fusarium spp. susceptibility profile to ITZ is essential. For this, the minimum inhibitory concentration (MIC) to ITZ was determined by the microdilution, according to the Clinical Laboratory Standards Institute (CLSI M38-A). The reference strain of F. solani (ATCC 36031) and five clinical isolates were selected to Mycology Collection of the Laboratory of Medical Mycology, UEM, Brazil. This clinical isolates were obtained from onychomycosis cases. The Candida parapsilosis (ATCC 22019) was included as control. ITZ was tested in the range 0.03– 512 µg/mL. The MIC values was considered as the concentration able to inhibit 50% of fungal growth when compared to the control. This values were obtained by absorbance determination, after 48 h of incubation with ITZ. The clinical isolates from F. solani showed low susceptibility to the antifungal ITZ. The MIC ranged between 256 and 32µg/mL. Two clinical isolates showed MIC values of 256 µg/mL, another MIC values of 128 µg/mL, the other two showed MIC values of 64 µg/mL and the fifth isolate showed MIC values of 32 µg/mL. The correlation between susceptibility and resistance for Fusarium species is a great challenge, since breakpoints have not been established for the in vitro susceptibility interpretation. Despite this, to know the antifungal susceptibility profile of the Fusarium spp. clinical isolates is important for the therapeutic success for onychomycosis, which in the most cases is multifactorial, dependent on patient adherence, degree of nail involvement, correct diagnosis and mainly the antifungal susceptibility of pathogen. These results also point out the need for the new therapeutic options development for the onychomycosis treatment by these emerging species.
Com ~200 mil publicações revisadas por pesquisadores do mundo todo, o Galoá impulsiona cientistas na descoberta de pesquisas de ponta por meio de nossa plataforma indexada.
Confira nossos produtos e como podemos ajudá-lo a dar mais alcance para sua pesquisa:
Esse proceedings é identificado por um DOI , para usar em citações ou referências bibliográficas. Atenção: este não é um DOI para o jornal e, como tal, não pode ser usado em Lattes para identificar um trabalho específico.
Verifique o link "Como citar" na página do trabalho, para ver como citar corretamente o artigo